HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy.

Abstract
Recognition of the essential role of dendritic cells (DCs) as professional antigen-presenting cells has prompted investigators to search for methods to use DCs as natural adjuvants in immunotherapy. A number of antigenic oligopeptides, recognized by CD8(+) cytotoxic T lymphocytes (CTLs) specific for cancer cells, have been applied in clinical trials using DCs. Such a monovalent vaccine with a single epitope for a particular type of HLA class 1 molecule would be effective. However, a polyvalent vaccine might be more potent. We designed a novel protein delivery system consisting of hydrophobized polysaccharides complexed with target proteins. The truncated HER2 protein encompassing 147 N-terminal amino acids, including the 9-mer HER2p63-71 peptide (HER2p63), TYLPTNASL, the human homologue of an antigenic murine tumor rejection peptide, was prepared. We report here that HLA-A2402(+) DCs could incorporate hydrophobized polysaccharide-truncated HER2 protein complexes and process the protein to present major histocompatibility complex class 1-binding HER2p63 peptide. The complexes enter DCs by phagocytosis, and then the truncated protein is processed through a pathway similar to that for endogenous proteins. DCs sensitized by these complexes primed and boosted HER2p63-specific CD8(+) T cells in the context of HLA-A2402. Vaccination with DCs incorporating these complexes completely suppressed lung metastases in a HER2-expressing murine tumor model. We also generated 3 CD4(+) clones reactive with different HER2- derived 25-mer peptides from lymph node cells in mice treated with CHP/HER2-147. Thus, hydrophobized polysaccharide-protein complexes are promising candidates for the construction of polyvalent vaccines.
AuthorsYasushi Ikuta, Naoyuki Katayama, Lijie Wang, Toshiharu Okugawa, Yoshiyuki Takahashi, Michael Schmitt, Xiaogang Gu, Masato Watanabe, Kazunari Akiyoshi, Hideo Nakamura, Kagemasa Kuribayashi, Junzo Sunamoto, Hiroshi Shiku
JournalBlood (Blood) Vol. 99 Issue 10 Pg. 3717-24 (May 15 2002) ISSN: 0006-4971 [Print] United States
PMID11986228 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, Neoplasm
  • Cancer Vaccines
  • Glucans
  • HER2p63 peptide
  • HLA-A Antigens
  • HLA-A*24:02 antigen
  • HLA-A24 Antigen
  • Macromolecular Substances
  • Peptide Fragments
  • Polysaccharides
  • pullulan
  • Receptor, ErbB-2
Topics
  • Amino Acid Sequence
  • Animals
  • Antigen Presentation
  • Antigens, Neoplasm (chemistry, immunology)
  • CD4-Positive T-Lymphocytes (immunology)
  • Cancer Vaccines (immunology)
  • Cells, Cultured
  • Clone Cells
  • Dendritic Cells (immunology)
  • Female
  • Glucans (chemistry)
  • HLA-A Antigens (metabolism)
  • HLA-A24 Antigen
  • Humans
  • Hydrophobic and Hydrophilic Interactions
  • Macromolecular Substances
  • Mice
  • Mice, Inbred BALB C
  • Monocytes (immunology)
  • Neoplasms (immunology, therapy)
  • Peptide Fragments (chemistry, immunology, metabolism)
  • Polysaccharides (chemistry)
  • Receptor, ErbB-2 (chemistry, immunology, metabolism)
  • T-Lymphocytes, Cytotoxic (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: